Stock 0LER TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Teva Pharmaceutical Industries Limited London S.E.

Equities

0LER

US8816242098

Pharmaceuticals

Delayed London S.E.
Other stock markets
 03:00:15 2024-06-17 am EDT 		5-day change 1st Jan Change
17.5 USD 0.00% Intraday chart for Teva Pharmaceutical Industries Limited +3.97% +67.70%
Jun. 14 Global markets live: Tesco, Adobe, Tyson Foods, GameStop, Teva... Our Logo
Jun. 14 Teva Pharmaceutical Sues Corcept Therapeutics Alleging Market Monopolization for Cushing's Syndrome Drug Korlym MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,702 10,576 8,835 10,129 11,703 19,435 - -
Enterprise Value (EV) 1 35,634 34,318 29,713 28,540 28,310 34,416 31,880 29,336
P/E ratio -10.8 x -2.65 x 21.1 x -4.3 x -20.9 x 17.8 x 12.3 x 9.84 x
Yield - - - - - - - -
Capitalization / Revenue 0.63 x 0.63 x 0.56 x 0.68 x 0.74 x 1.21 x 1.17 x 1.14 x
EV / Revenue 2.11 x 2.06 x 1.87 x 1.91 x 1.79 x 2.15 x 1.92 x 1.72 x
EV / EBITDA 7.61 x 6.99 x 6.05 x 6.21 x 5.88 x 7.22 x 6.25 x 5.52 x
EV / FCF 17.4 x 53.8 x 126 x 27.4 x 33.6 x 14.5 x 10.3 x 8.62 x
FCF Yield 5.76% 1.86% 0.79% 3.65% 2.97% 6.9% 9.71% 11.6%
Price to Book 0.77 x 1.05 x 0.86 x 1.28 x 1.56 x 2.06 x 1.64 x 1.35 x
Nbr of stocks (in thousands) 1,092,089 1,095,972 1,103,007 1,110,645 1,120,971 1,132,592 - -
Reference price 2 9.800 9.650 8.010 9.120 10.44 17.16 17.16 17.16
Announcement Date 2/12/20 2/10/21 2/9/22 2/8/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 16,887 16,659 15,878 14,925 15,846 16,002 16,625 17,048
EBITDA 1 4,685 4,912 4,911 4,598 4,818 4,769 5,102 5,317
EBIT 1 4,142 4,388 4,401 4,139 4,361 4,285 4,660 4,836
Operating Margin 24.53% 26.34% 27.72% 27.73% 27.52% 26.78% 28.03% 28.37%
Earnings before Tax (EBT) 1 -1,265 -4,406 658 - -624 -99 3,194 3,302
Net income 1 -999 -3,990 417 -2,353 -559 809.1 1,375 1,610
Net margin -5.92% -23.95% 2.63% -15.77% -3.53% 5.06% 8.27% 9.45%
EPS 2 -0.9100 -3.640 0.3800 -2.120 -0.5000 0.9616 1.399 1.745
Free Cash Flow 1 2,053 638 236 1,042 842 2,375 3,097 3,403
FCF margin 12.16% 3.83% 1.49% 6.98% 5.31% 14.84% 18.63% 19.96%
FCF Conversion (EBITDA) 43.82% 12.99% 4.81% 22.66% 17.48% 49.8% 60.7% 64.02%
FCF Conversion (Net income) - - 56.59% - - 293.5% 225.16% 211.34%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/12/20 2/10/21 2/9/22 2/8/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4,100 3,661 3,786 3,595 3,884 3,661 3,878 3,850 4,457 3,819 4,027 4,040 4,121 3,845 3,976
EBITDA 1 1,373 1,135 1,134 1,089 1,240 899 1,125 1,134 1,660 1,005 1,136 1,219 1,359 - -
EBIT 1 1,248 1,013 1,019 977 1,130 785 1,011 1,020 1,546 892 1,027 1,108 1,211 949.3 1,090
Operating Margin 30.44% 27.67% 26.91% 27.18% 29.09% 21.44% 26.07% 26.49% 34.69% 23.36% 25.49% 27.43% 29.38% 24.69% 27.43%
Earnings before Tax (EBT) 1 -175 -971 -1,160 - -1,100 - - 75 507 -467 107 127 133 - -
Net income 1 -159 -955 -232 56 -1,221 -205 -863 80 461 -139 39 56.5 -15.77 - -
Net margin -3.88% -26.09% -6.13% 1.56% -31.44% -5.6% -22.25% 2.08% 10.34% -3.64% 0.97% 1.4% -0.38% - -
EPS 2 -0.1400 -0.8600 -0.2100 0.0500 -1.100 -0.1800 -0.7700 0.0700 0.4100 -0.1200 -0.4009 0.002380 0.8995 - -
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/9/22 5/3/22 7/26/22 11/3/22 2/8/23 5/10/23 8/2/23 11/8/23 1/31/24 5/8/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 24,932 23,742 20,878 18,411 16,607 14,981 12,445 9,901
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 5.322 x 4.833 x 4.251 x 4.004 x 3.447 x 3.141 x 2.439 x 1.862 x
Free Cash Flow 1 2,053 638 236 1,042 842 2,375 3,097 3,403
ROE (net income / shareholders' equity) 18.3% 11.8% 28.1% 30.9% 37.9% 28.9% 30.1% 26.1%
ROA (Net income/ Total Assets) 4.45% 5.24% 5.81% 6.13% 6.62% 2.94% 5.17% 4.69%
Assets 1 -22,466 -76,212 7,179 -38,354 -8,438 27,507 26,624 34,356
Book Value Per Share 2 12.80 9.160 9.320 7.110 6.710 8.320 10.50 12.70
Cash Flow per Share 2 0.6900 1.110 0.7200 1.430 1.220 2.490 2.860 3.250
Capex 1 525 578 562 548 526 517 546 562
Capex / Sales 3.11% 3.47% 3.54% 3.67% 3.32% 3.23% 3.28% 3.3%
Announcement Date 2/12/20 2/10/21 2/9/22 2/8/23 1/31/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Teva Pharmaceutical Industries Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
17.16 USD
Average target price
18.34 USD
Spread / Average Target
+6.85%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NOVO NORDISK A/S Stock Novo Nordisk A/S
+42.47% 630B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.15% 350B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.77% 328B
ABBVIE INC. Stock AbbVie Inc.
+8.79% 298B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.96% 246B
ROCHE HOLDING AG Stock Roche Holding AG
+0.74% 225B
NOVARTIS AG Stock Novartis AG
+10.95% 218B
AMGEN INC. Stock Amgen Inc.
+3.68% 160B
PFIZER, INC. Stock Pfizer, Inc.
-4.38% 156B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TEVA Stock
  4. 0LER Stock
  5. Financials Teva Pharmaceutical Industries Limited